Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

Diabetes is a chronic medical condition that affects the body’s ability to regulate blood sugar or glucose, a vital energy ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

A drug normally used to treat diabetes can significantly reduce your risk of developing dementia, new research has revealed.

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study.

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety ...

Antidiabetics Market is estimated to reach US$ 223 Billion, displaying a CAGR of 9.6% during the assessment period from 2022- ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...